COVID-19 and psoriasis: Recommendation for patients on regular infliximab therapy

Dermatol Ther. 2020 Nov;33(6):e14472. doi: 10.1111/dth.14472. Epub 2020 Nov 9.

Abstract

During COVID-19 outbreak hospitals were congested and infliximab was interrupted. Thus, we performed this observational study to understand the consequent burden of complications in these special cluster of psoriatic patients. We followed up 56 psoriatic patients who were receiving Infliximab treatment by telephone. The majority of patients had lesions exacerbation, accompanied by anxiety emotion. It is suggested that reserving common drugs for psoriasis at home is necessary. Besides, telemedicine should be advocated as a main medical visit mode during the outbreak of COVID-19.

Keywords: infliximab; psoriasis; telemedicine.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • COVID-19*
  • Dermatologic Agents / supply & distribution
  • Dermatologic Agents / therapeutic use*
  • Drug Substitution
  • Female
  • Health Services Accessibility*
  • Humans
  • Infliximab / therapeutic use*
  • Male
  • Middle Aged
  • Psoriasis / diagnosis
  • Psoriasis / drug therapy*
  • Psoriasis / immunology
  • Telemedicine*
  • Treatment Outcome

Substances

  • Dermatologic Agents
  • Infliximab